Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7440452 | 0.98 | DGAT1 (0.39) | DGAT1PDE10AKLKB1 | |
| SCHEMBL7447421 | 0.85 | DGAT1 (0.40) | DGAT1PDE10AKLKB1 | |
| SCHEMBL7495729 | 0.81 | DGAT1 (0.38) | DGAT1PDE10AKLKB1 | |
| SCHEMBL21465294 | 0.81 | DGAT1 (0.43) | DGAT1PDE10AKLKB1 | |
| SCHEMBL23701940 | 0.80 | DGAT1 (0.37) | DGAT1PDE10AKLKB1 | |
| SCHEMBL1485428 | 0.78 | DGAT1 (0.41) | DGAT1PDE10AKLKB1 | |
| SCHEMBL25292277 | 0.78 | DGAT1 (0.41) | DGAT1PDE10AKLKB1 | |
| SCHEMBL12963688 | 0.78 | DGAT1 (0.50) | DGAT1PDE10AKLKB1 | |
| SCHEMBL23714041 | 0.77 | DGAT1 (0.35) | DGAT1PDE10AKLKB1 | |
| SCHEMBL1485180 | 0.76 | DGAT1 (0.40) | DGAT1PDE10AKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | EPOR, EZR, CD47 | DGAT1 3260/4885PDE10A 1421/4885KLKB1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.